Ramos AJT, Ruiz JM

Idioma: Español
Referencias bibliográficas: 18
Paginas: 161-165
Archivo PDF: 233.15 Kb.

FRAGMENTO

La proporción de pacientes pediátricos con experiencia en las tres familias de fármacos antirretrovirales orales disponibles en niños (ITIAN, ITINN, e IP) está en aumento. En niños con fracaso virológico, la prevalencia de resistencia a las tres familias de fármacos orales es variable, estimada entre 27 y 42% en diferentes países europeos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol. 2007 ;79:1261-9

2. Larrú B, De José MI, Bellón JM, Gurbindo MD, León JA, Ciria L, et al. Prevalencia de resistencia a fármacos antirretrovirales en España. An Esp Pediatr 2007 An Pediatr (Barc) 2007; 67:104-8

3. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Triple-class virologic failure in HIVinfected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170: 410-9.

4. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Actualización 16 Agosto 2010. Disponible en http:// aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf

5. 5-PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009;10:591-613.

6. 6- Lee KJ, Shingadia D, Pillay D, Walker AS, Riordan A, Menson E, Duong T, et al. Transient viral load increases in HIVinfected children in the U.K. and Ireland: what do they mean? Antivir Ther. 2007;12:949-56: 61-7.

7. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H, for the PENTA Steering Committee. Adherence to prescribed antiretroviral therapy in with human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 56-62.

8. The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Antiretroviral therapy initiation with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: a randomised trial. Lancet Infect Dis (en prensa)

9. Rudin C, Burri M, Shen Y, Rode R, Nadal D. Long term safety and effectiveness of ritonavir, nelfinavir and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J 2008, 27 : 431-437.

10. Ramos JT. Boosted Protease Inhibitors as a therapeutic option in the treatment of HIV-infected children. HIV Med 2009; 9:536- 47.

11. Ramos JT, De José MI, Dueñas J, Fortuny C, González Montero R, Mellado MJ, et al. Safety and efficacy of lopinavir/ritonavir in HIV-infected children experienced with 3 classes of antiretrovirals. Pediatr Infect Dis J 2005; 24: 867-873.

12. Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, et al. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J 2006 ;25:809-14.

13. Palladino C, Briz V, Policarpo SN, Silveira LF, de José MI, González- Tomé MI, et al. Long-term efficacy and safety of fosamprenavir in HIV-infected pediatric patients in clinical practice. Pediatr Infect Dis J 2010; 29: 563-566.

14. Salazar JC, Cahn P, Yogev R, Negra MD, Castelli-Gattinara G, Fortuny C, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 2008;22:1789-98.

15. Blanche S, Bologna R, Rugina S, Cahn P, Flynn P, Fortuny C, et al. Safety and efficacy of darunavir coadministration with lowdose ritonavir in treatment experienced children and adolescents at week 24. AIDS 2009; 23: 2005-2013

16. 16-Thuret I, Chaix ML, Tamalet C, Reliquet V, Firtion G, Tricoire J, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009;23:2364- 6.

17. 17- Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A; T20-310 Study Group. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007;26:799-805.

18. 18- Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.